Table 1 Patient information including treatment details, tracked mutations and sub-clone indications
From: Single cell analysis of clonal architecture in acute myeloid leukaemia
Patient | Patient treatment details | Tracked mutations | No. clones CD33+CD3− fraction | No. clones CD34+CD33− fraction | No. clones in xenografts | Total detected clones |
|---|---|---|---|---|---|---|
1 | Died post induction | TET2 x2 (one not tracked), DNMT3A, NPM1,FLT3-ITD | 4 | 3 | 3 | 5 |
2 | Refractory to primary induction | WT1, IDH2,NRAS, NPM1,GATA1 | 3 | 2 | 2 | 3 |
3 | Relapsed | WT1,NPM1,FLT3 x2 | 6 | 5 | 2 | 6 |
4 | Received palliative chemotherapy | DNMT3A,TET2,CBL,FLT3-ITD, NPM1 | 2 | 2 | 4 | 4 |
5 | Not offered chemotherapy as had co-existing colon cancer | DNMT3A,TET2,ZRSR2,NPM1, FLT3-ITD, PTPN11, NF1 | 4 | 3 | 5 | 6 |
6 | Responded to induction; remains in remission | DNMT3A (no tracked), TET2,NPM1 | 2 | 2 | 2 | 2 |
7 | Went into remission; developed therapy related MDS | DNMT3A, TET2 x2, NPM1,FLT3, CTNNA1 (not tracked) | 2 | 2 | 1 | 4 |
8 (diagnostic sample) | Relapsed | DNMT3A,MLL5,NPM1, FLT3-ITD,GATA2, TET2 | 1 | 2 | 2 | 3 |
8 (relapse sample) | Died | DNMT3A,MLL5,NPM1,FLT3-ITD,GATA2, TET2 | 1 | 1 | 1 | 2 |
9 (diagnostic sample) | Relapsed | WT1,NPM1,FLT3-ITD, MLL3 and UTY (not tracked) | 1 | 1 | 1 | 1 |
9 (relapse sample) | Died | WT1,NPM1,FLT3-ITD, MLL3 and UTY (not tracked) | 1 (bulk cells) | – | 1 | 1 |
10 (diagnostic sample) | Relapsed | DNMT3A,NPM1, TP53, FLT3 x2 (neither tracked) | 2 | 3 | Did not engraft | 3 |
10 (relapse sample) | Died | DNMT3A,NPM1, TP53 FLT3 x2 (neither tracked) | 3 (bulk cells) | – | 2 | 3 |
